翔宇医疗(688626) - 2025 Q4 - 年度业绩

Financial Performance - Total revenue for 2025 reached 767.75 million CNY, a year-on-year increase of 3.26%[3] - Net profit attributable to shareholders decreased by 23.55% to 78.70 million CNY[3] - Net profit excluding non-recurring gains and losses fell by 34.48% to 58.95 million CNY[3] - Basic earnings per share decreased by 22.73% to 0.51 CNY[3] - The weighted average return on equity decreased by 1.32 percentage points to 3.70%[3] Assets and Equity - Total assets increased by 11.64% to 3,268.63 million CNY[3] - Shareholders' equity attributable to the parent company rose by 1.54% to 2,070.10 million CNY[3] Operational Factors - The decline in net profit was primarily due to increased R&D expenses and depreciation costs[6] - The company continues to focus on technological innovation and improving operational efficiency[5] Report Accuracy - There are no significant uncertainties affecting the accuracy of the performance report[7]